Cizzle Biotechnology plc

Cizzle Biotechnology (AIM: CIZ) has reported further progress towards commercialising its CIZ1B blood test for early-stage lung cancer in the US, following successful validation at a CLIA-accredited laboratory and plans to expand testing through larger facilities, including BioBridge Global. However, the company has also confirmed a significant change to its licensing agreement with US partner Cizzle Bio, which has paid US$590,000 of the US$2.4 million originally due by December 2026. The remaining US$1.81 million has now been deferred until December 2027, reflecting slower commercial rollout and pressures within the US laboratory market. Importantly, the revised agreement allows Cizzle to receive its 10% royalty on gross sales from the outset, rather than offsetting royalties against advance payments, while providing an option to convert outstanding payments into equity in Cizzle Bio. The company is targeting private healthcare, occupational health and insurance markets, although early sales volumes remain unquantified and further funding could be required if payments are delayed.@CizzlePlc

Cizzle Biotechnology (AIM: CIZ) has announced further progress in developing its CIZ1B blood test for the early detection of lung cancer, with the company invited to present at the SYNLAB Innovation Academy Symposium on 5 November 2026. The presentation will include technical evaluation studies currently underway at the Christie Pathology Partnership in Manchester, an important step towards independent clinical validation and potential adoption within healthcare systems. Recent research published in the peer-reviewed Journal of Applied Laboratory Medicine demonstrates improvements in the accuracy and reproducibility of the CIZ1B biomarker test, supported by the company’s ongoing collaboration with the University of York. Crucially, the technology now uses scalable reagents designed to support future high-throughput diagnostic testing, potentially enabling wider commercial deployment. Management believes the latest results meet the analytical performance standards required by major healthcare providers, although clinical validation and regulatory approval remain important milestones before commercial adoption.@CizzlePlc